HOSP Partners are organizations that align with the commitment and advocacy efforts to improve patient outcomes and to innovate patient care through the integrated specialty pharmacy model. These organizations understand the value of collaboration in the advancements in research, advocacy, and education.
To learn more about the HOSP Partners, click on the logo below to preview their profile that provides information on their organization.
Madrigal Pharmaceuticals Inc.
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Company URL: https://www.madrigalpharma.com/